参考文献

1. SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics. CA Cancer J Clin, 2018,68(1):7－30．

2. TRUMP D L. Commentary on Cabozantinib in patients with advanced prostate cancer: results of a phase Ⅱ randomized discontinuation trial. J Clin Oncol,2013,31 (4):412－419．

3. LLOVET J M, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med,2008,359(4):378－390．

4. CHENG A L, KANG Y K, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia－Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised,double－blind, placebo －controlled trial. Lancet Oncol,2009,10 (1):25－34．

5. KUDO M, FINN R S, QIN S, et al. Lenvatinib versus sorafenib in first －line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non－inferiority trial. Lancet,2018,391(10126):1163－1173．

6. BRUIX J,QIN S,MERLE P,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):a randomised,double-blind,placebo-controlled,phase 3 trial. Lancet,2017,389(10064):56－66．

7. WANG S N,CHUANG S C,LEE K T. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res,2014,44(5):523－531．

8. YOPP A C,MANSOUR J C,BEG M S,et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol,2014,21(4):1287－1295．

9. NAGY J A, BROWN L F, SENGER D R, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta,1989,948(3):305－326．

10. BANERJEE S C. Metastasis to the mandible. Oral Surg Oral Med Oral Pathol, 1967,23(1):71－77．

作者简介：徐俊杰，2018级临床医学博士后，主攻方向为肝癌的微创精准诊疗。

指导老师：蔡秀年，教授，主任医师，浙江大学医学院附属邵逸夫医院，主攻方向为微创外科。